Emerging Insights in Diagnosing Recurrent Prostate Cancer in Men with Low PSA Levels
In a recent video interview, Ashesh Jani, M.D., discussed a subset analysis from the SPOTLIGHT trial that examined the utility of the PET PSMA agent flotufolastat F 18 (Posluma) for detecting prostate cancer recurrence in men with low PSA levels lower than 1 ng/mL.
Ashesh Jani, M.D., said there has been a considerable increase in referred post-prostatectomy patients with lower prostate-specific antigen (PSA) levels, making it increasingly important to have diagnostic tools that can help identify recurrent prostate cancer in this patient population.
In a presentation at the recent American Society for Radiation Oncology (ASTRO) conference, Dr. Jani discussed key research findings from a post-hoc analysis of the phase 3 SPOTLIGHT trial that looked at the use of the positron emission tomography (PET) prostate-specific membrane antigen (PSMA) agent flotufolastat F 18 (Posluma, Blue Earth Diagnostics) for patients with suspected prostate cancer recurrence and PSA levels lower than 1 ng/mL.
In a recent interview, Dr. Jani said he and his colleagues found that use of flotufolastat F 18 detected prostate cancer recurrence in 68 percent of patients with a PSA level less than 1 ng/mL and 64 percent of men with PSA levels lower than 0.5 ng/mL.
“With the advent of molecular imaging and novel radiotracers, we’re able to see the source of PSA at lower PSA levels,” noted Dr. Jani, a professor in the Department of Radiation Oncology at the Emory University School of Medicine and the James C. Kennedy Professor in Prostate Cancer at the Winship Cancer Institute of Emory University.
(Editor’s note: For related content, see “Study: PET/CT Multivariate Model Enhances Accuracy for Diagnosing Prostate Cancer,” “Emerging PET Radiotracer May Offer Multiple Advantages in Detecting Prostate Cancer” and “Could a New PSMA PET Agent Improve Detection of Distant Metastatic Lesions in Patients with Prostate Cancer?”)
The use of flotufolastat F 18 also led to the detection of extrapelvic lesions in 39 percent of patients with PSAs between 0.5 and 1 ng/mL, and 21 percent of men with PSA levels lower than 0.5 ng/mL, according to Dr. Jani.
“There was significant potential for changing management decisions based on this test,” emphasized Dr. Jani.
(Editor’s note: For related content on prostate cancer imaging, click here.)
For more insights from Dr. Jani, watch the video below.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
MRI Study at ARRS Raises Questions About Disparities in Detection of MASLD
May 3rd 2025New research revealed that Hispanic Americans with evidence of hepatic steatosis on MRI but no formal diagnosis of MASLD had over a fourfold higher risk of developing hepatocellular carcinoma in comparison to those who had a formal diagnosis of MASLD.
FDA Clears MRI-Based AI Segmentation of Organs at Risk During Radiation Therapy
May 2nd 2025Capable of segmenting over 37 organs and structures in the head, neck and pelvis, the MR Contour DL software is currently being showcased at the European Society for Radiotherapy and Oncology (ESTRO) conference.
